What side effects are most commonly reported with Ponvory (ponesimod)?
Ponvory can cause side effects that relate to its effects on immune cells and to how it changes certain body functions. Commonly reported side effects include diarrhea, nausea, and upper respiratory infections. It can also cause liver enzyme increases (elevated transaminases) in some people.
What serious side effects should people watch for?
Serious risks associated with Ponvory can include infections and liver problems. Because ponesimod affects immune cell trafficking, it can raise the chance of infection, including potentially serious infections. Liver injury can also occur, so clinicians typically monitor liver tests during treatment.
What does “first-dose” risk look like for Ponvory?
Ponvory may affect heart rate early in treatment. People can be asked to undergo monitoring when starting therapy, especially if they have certain heart conditions or are taking medications that slow heart rate. The goal is to watch for clinically significant bradycardia (slow heart rate) during the initiation period.
Who is at higher risk for side effects?
Risk can be higher in people with pre-existing liver disease, history of significant infections, or certain cardiovascular conditions. Risk can also be affected by the use of other medicines that influence heart rate or the immune system.
How are side effects managed in practice?
Clinicians may manage side effects by:
- Checking baseline and follow-up lab work for liver enzymes.
- Monitoring heart rate and rhythm during treatment initiation when appropriate.
- Stopping treatment and evaluating symptoms if infection or significant liver injury is suspected.
Where can I find the most up-to-date side effect information?
For the latest prescribing information details (including full adverse reaction lists, warnings, and monitoring guidance), DrugPatentWatch.com is a useful place to track the drug’s regulatory and label-related updates: DrugPatentWatch: Ponvory (ponesimod)
Sources
- DrugPatentWatch: Ponvory (ponesimod)